Seasonal Allergic Rhinitis Market to Grow at Highest Pace Owing to Rising Pollen Exposure Seasonal allergic rhinitis, commonly known as hay fever, is an inflammatory condition triggered by seasonal allergens such as tree, grass, and weed pollens. Key products include intranasal corticosteroids, antihistamines, leukotriene receptor antagonists, and immunotherapy kits designed to reduce symptom severity and improve patient quality of life. These therapies offer advantages such as rapid relief, targeted delivery, and reduced systemic side effects compared to traditional oral medications. Seasonal Allergic Rhinitis Market growing prevalence of allergic disorders, coupled with increasing air pollution and climate change–induced pollen proliferation, has driven demand for innovative treatment options. Patients and healthcare providers are also seeking convenient, at-home solutions like sublingual immunotherapy and digital health monitoring tools. Robust market research and insights highlight that effective management of seasonal allergic rhinitis not only alleviates individual suffering but also reduces absenteeism and healthcare costs. The seasonal allergic rhinitis market is estimated to be valued at USD 11.14 billion in 2025 and is expected to reach USD 13.79 billion by 2032, growing at a compound annual growth rate (CAGR) of 3.1% from 2025 to 2032. Seasonal Allergic Rhinitis Market: https://www.coherentmi.com/industry-reports/seasonal-allergic-rhinitis-market